The Whickham Survey evaluated vascular events over 20 yr in community-dwelling subjects stratified by thyroid function and thyroid autoantibody status. No association between ischemic heart disease (IHD) and a composite autoimmune thyroid disease group, comprising individuals with subclinical hypothyroidism (SCH), with positive thyroid antibodies or those using levothyroxine, was found. This result appears to be at odds with the findings of other cohort studies.
S
ubclinical hypothyroidism (SCH) is prevalent in 5-15% of the population and its frequency increases with age (1, 2) . It has been debated for some time whether SCH is associated with ischemic heart disease (IHD) and increased mortality (3) (4) (5) (6) (7) . The Whickham Survey is a pivotal study that investigated the long-term consequences of thyroid dysfunction and has provided vital data on the demographics of thyroid diseases in the population (8) .
This study did not find an association between IHD events and a composite autoimmune thyroid disease phenotype, comprising individuals with raised serum TSH and normal thyroid hormones, those with positive thyroid antibody levels but normal thyroid function, and those treated with levothyroxine since the first survey (9) . It remains unclear whether there was an association between SCH and IHDrelated mortality in this cohort. In addition, there has been a misconception in some of the published literature regarding this association (10, 11) . We therefore reanalyzed the data to investigate whether such a relationship exists.
Subjects and Methods

Study population
The Whickham Survey is a population-based cross-sectional study of community-dwelling adults in an urban area close to Gateshead/Newcastle in northern England. The full details of the cross-sectional and its 20-yr follow-up studies have been published previously (2, 8, 9) . Briefly, a randomly selected group of 2779 individuals were first studied in 1972-1973 and history of medical conditions, demographic details, physical examination, and electrocardiograph (ECG) and biochemical samples for lipids, thyroid function, and thyroid antibodies (antimicrosomal) performed. At the 20-yr follow-up study, cause of death, casenote examination of those who had died, and further examination of the survivors was performed. Participants with known thyroid disease or on medications that could affect thyroid function (n ϭ 60) and IHD (n ϭ 243) at baseline were excluded from this analysis. Furthermore, people with overt hypothyroidism (TSH Ͼ15 mIU/liter; n ϭ 13) were also excluded. Details of medical conditions and/or cause of death could not be ascertained at follow-up in 52 individuals, and these were also excluded from this study, leaving data from a total of 2376 individuals who had been followed up for 20 yr.
Thyroid status and ascertainment of events
At baseline, SCH was defined as serum TSH between 6.0 and 15.0 mIU/liter with normal total T 4 levels (46 -174 nmol/liter). The baseline survey used a first-generation TSH assay that overestimated TSH levels (12) . Hence, the normal range of TSH was up to 6.0 (the 97.5th centile in the cohort with negative thyroid antibodies and not on medications affecting thyroid function) rather than 4.5 mIU/liter as it would be today using ultrasensitive TSH assays. Therefore, to make the range of TSH levels in SCH individuals comparable with the current range of 4.5-10.0 mIU/ liter, we used a range of 6.0 -15.0 mIU/liter in the reanalysis. All individuals with TSH levels between 0.3 and 5.9 mIU/liter were classed as being euthyroid; total T 4 levels were not used for this categorization because they might be elevated due to some medications (such as estrogens). Positive thyroid antibodies were defined as increased titers of antimicrosomal antibodies. Details of all the laboratory methodology have been previously described (2) . At the end of the follow-up period of 20 yr, the status of participants was determined. IHD events were defined by Rose angina questionnaires, ECG changes as per the Minnesota code, or hospital admission for IHD events that were confirmed by ECG or serial cardiac enzymes. For deceased patients, cause of death was ascertained by examining death certificates and coding them as per criteria of the International Classification of Diseases, ninth revision, and other medical conditions were determined by examining hospital and primary care records.
Statistical analysis
Baseline characteristics of the analyzed sample were compared stratified by thyroid status, using unpaired t test or 2 test for continuous and categorical variables, respectively. Variables that were not normally distributed were log transformed before analysis. Baseline vascular risk factors that were significantly different between the two thyroid groups were further analyzed by linear regression after adjusting for confounding variables (age, gender, weight, smoking, and relevant medications) to investigate whether thyroid function was independently associated with those risk factors. Analysis of IHD events and mortality as hazard ratios (HR) in the euthyroid and SCH groups at baseline was performed by multivariable Cox-regression analysis after adjusting for IHD risk factors and thyroid hormone use during follow-up (full model). These IHD risk factors were age, gender, social class (class 1-6, as a surrogate marker of socioeconomic status and educational level based on occupation), body weight in kilograms, systolic and diastolic blood pressure in millimeters of mercury, serum total cholesterol in millimoles per liter, smoking (current smoker, ex-smoker, or never-smoker), and cerebrovascular disease and diabetes mellitus (both as categoricals). The analyses were repeated after excluding the variable of thyroid hormone use during follow-up (model B). Finally, thyroid antibody status scored as positive or negative at baseline was added to the equation (model C). The Cox-regression model was stratified by gender initially. However, because there was no heterogeneity between sexes (P for interaction ϭ 0.15) with respect to thyroid status, both men and women were analyzed as a whole for greater statistical power. Similarly, there was no interaction between any outcome and age (less than or greater than 65 yr) (P for interaction Ͼ0.2). In addition, a further analysis restricted to SCH participants at baseline was performed investigating the above outcomes after adjusting for baseline variables and stratified for thyroid hormone treatment during follow-up (categorical as yes/no) was performed. SPSS 10.0 (Chicago, IL) was used to perform all analyses.
Results
In this reanalysis, after exclusion of individuals with known thyroid disease or IHD and on medications that could affect thyroid function, the majority of participants at baseline were euthyroid (95.9%; mean age 45.3 yr, range 18 -92). The prevalence of SCH was 4.1% (mean age 49.9 yr, range 18 -87) and was higher in women, older individuals, nonsmokers, and those with positive thyroid antibodies ( Table 1) . As expected, serum TSH levels were higher and thyroxine concentrations lower in the SCH group compared with euthyroid individuals. Forty-five participants (three men and 42 women: 25 euthyroid and 20 SCH at baseline) had been treated with levothyroxine over the 20-yr follow-up period.
Association between thyroid status and IHD risk factors at baseline
Systolic and diastolic blood pressure levels were higher in the SCH group, as were total cholesterol levels ( Table 1) . Multiple linear regression analysis, after adjusting for other IHD risk factors as outlined in Subjects and Methods, showed that SCH was significantly associated only with higher systolic blood pressure (r 2 ϭ 0.38, df ϭ 6, standard-ized ␤-coefficient ϭ 0.03, P ϭ 0.03) but not diastolic blood pressure or serum cholesterol levels (data not shown).
Association between thyroid status at baseline and incident IHD events and mortality (Table 2 ) There were 419 IHD events (fatal and nonfatal) over the follow-up period. There was a positive association between SCH at baseline and incident IHD with adjusted HR (95% confidence interval) of 1.76 (1.15-2.71; P ϭ 0.01), after multivariate adjustment (full model). Excluding thyroid hormone use during follow-up from the multivariate model (model B), showed a reduction in the association between SCH and IHD events, HR of 1.53 (0.97-2.45; P ϭ 0.07).
There were 165 deaths due to IHD in the cohort over the subsequent 20 yr of follow-up. IHD mortality was higher in the SCH participants than in the euthyroid individuals with adjusted HR of 1.79 (1.02-3.56; P ϭ 0.05), in the full model (Fig. 1) . However, when subsequent thyroid hormone use was excluded from the multivariate model (model B), this association was lost [HR of 1.45 (0.73-2.89); P ϭ 0.28]. Other causes of mortality (due to cerebrovascular disease, trauma, infection, and malignancy) were similar in both groups.
There were a total of 595 deaths in the entire cohort, and all-cause mortality was not different in the SCH group compared with euthyroid participants, with an adjusted HR of 1.29 (0.87-1.92) (full model); the exclusion of subsequent thyroid hormone use did not change the results fundamentally. The addition of thyroid antibody status to the full multivariate model (model C) did not change the above results for any outcome significantly ( Table 2) .
Association of mortality and IHD events in SCH participants stratified by thyroid hormone treatment
Over the 20 yr of follow-up, 20 of the 91 participants with SCH at baseline were commenced on treatment with levothyroxine therapy (no follow-up data were available for six SCH participants). Women and those with higher serum cholesterol levels at baseline were more likely to be treated; age, other chronic conditions (hypertension, diabetes mellitus, and cerebrovascular disease), smoking history, and serum TSH levels were not significantly different between the two groups. At follow-up, there were 24 
Discussion
The initial report of the 20-yr follow-up study of the Whickham Survey cohort did not find an association be-
FIG. 1.
The P values are derived from assessing the HRs for each group based on thyroid function at baseline and adjusted for age, gender, social class, weight, cerebrovascular disease, diabetes mellitus, smoking, systolic and diastolic blood pressure, total cholesterol levels, and thyroid hormone use during follow-up. Hazard plots for fatal and nonfatal IHD events (A), IHD mortality (B), and all-cause mortality (C) in the Whickham cohort over 20 yr are stratified by thyroid status at baseline.
tween IHD events and a composite of thyroid phenotypes including people with either SCH or positive thyroid antibody levels or on levothyroxine treatment, irrespective of their serum TSH levels (9) . In the current analysis, we show that there is an association of IHD and IHD-related mortality in people with SCH. This is in keeping with the results of several other studies that have assessed this association (3, 4, 7). Furthermore, our subgroup analysis of SCH participants comparing thyroxine-treated and untreated participants, although not a randomized controlled trial, is the first data to suggest improvement in mortality with treatment over an extended period of follow-up, as far as we are aware. Interestingly, in the Cardiovascular Health Study, the risk of heart failure was considerably lower and at similar levels to that of euthyroid individuals in thyroxine-treated SCH individuals (13) . In addition, our reanalysis of the data after including people with SCH alone has shown that the risk of IHD events was not related to antibody status at baseline. One obvious explanation for the apparent discrepant findings of this analysis is that the inclusion of treated overtly hypothyroid individuals in the original follow-up study may have diluted the observed risk of IHD events. The relationship between SCH and IHD has been controversial, and not all studies have shown a positive association (3-7) . The inconsistency in results may be due to differences in the populations as well as the duration of follow-up of the various studies. Metaanalyses of IHD events and SCH have shown that such an association probably exists (14) , especially in younger cohorts (15) . There have been suggestions that any possible increase in vascular risk in SCH may be mediated via conventional risk factors and that these factors improve with levothyroxine treatment (16) . It is also possible that emerging or nonconventional risk factors may be responsible; endothelial dysfunction (17) and elevated C-reactive protein levels (18) have been shown to be associated with SCH in some studies. The other possible reason for increased IHD risk might be that the risk factors exert their effect at the outset and that any change over the subsequent years does not influence outcomes.
The strengths of this study include the long duration of follow-up, the rigorous methods of assessing outcomes, and the low number of individuals who were lost to follow-up. Furthermore, this study also tried to probe the reasons that people with SCH have an increased IHD risk. It is interesting to note that a cohort study from Australia, with participant numbers and follow-up period similar to the Whickham study, showed a similar result (4) .
The limitations of this study were that all individuals were classed as either euthyroid or with SCH based on one blood test. Thus, some individuals with transient TSH elevation may have been labeled as SCH. If anything, this factor may actually have diluted the evidence for association that we have found between SCH and IHD by including some euthyroid individuals with transient TSH elevation in the SCH group. Furthermore, some individuals with SCH may have progressed to overt hypothyroidism before being detected by their primary care practitioners or at the 20 yr follow-up survey, thereby increasing their vascular risk for the time period without treatment. However, some of these patients would have commenced T 4 treatment once diagnosed (via primary care practitioners). Although we tried to account for most variables affecting vascular risk in our multivariate analysis, we may not have accounted for all and other, currently unmeasured, risk factors may have a role. For instance, the use of antihypertensive medication during follow-up or the timing of treatment with T 4 has not been assessed in this analysis. In addition, as mentioned previously, due to serum TSH being measured by a first-generation assay, the lower cutoff of 6.0 mIU/liter used in this study may not be identical with similar levels using current assays. An ad- ditional minor consideration is that it is possible one or two individuals with central hypothyroidism were misclassified as euthyroid at follow-up due to reliance solely on TSH in defining the euthyroid state. Similarly, individuals with subclinical hyperthyroidism were not identified due to the inability of the first-generation serum TSH assay to detect TSH levels lower than 0.3mIU/liter. Therefore, individuals with subclinical hyperthyroidism were grouped with euthyroid individuals and may have inflated the apparent vascular risk of the latter (19) . The role of treatment of SCH in reducing IHD or IHDrelated mortality has not been studied so far. There is some evidence that certain IHD risk factors may improve with levothyroxine treatment (20 -23) . Based on the results of this analysis, it would appear that treatment of SCH may be associated with reduced mortality as well as IHD events. However, there is a potential for bias in our retrospective observational analysis (i.e. SCH patients who were treated may have been more health conscious leading to a healthy user bias). In addition, the total number of events in each group of SCH participants (treated and nontreated) are small. Therefore, these results need to be interpreted with caution until a randomized controlled trial is available to provide level 1 evidence to inform this question.
In conclusion, this reanalysis of the Whickham Survey cohort has found an association of SCH with IHD and IHD-related mortality. The prevalent conventional risk factors at baseline, apart from systolic blood pressure, do not explain this association. The original analysis of the 20 yr follow-up of the Whickham Survey cohort had included individuals with normal thyroid function and/or positive antibodies, as well as treated hypothyroid individuals in a composite autoimmune thyroid disease group, but did not find this association. The results of this reanalysis are consistent with several other long-term cohort studies that have investigated this association.
